Hormone Replacement Therapy for Longevity: How HRT Can Drop Biological Age by 5-25 Years

Women on well-managed HRT protocols frequently show biological age reductions of 5 to 25 years, measured through IgG glycosylation — the molecular switches that control chronic inflammation. This is not a theoretical benefit: it is measurable, reproducible, and visible within months of initiating therapy.

For a deeper understanding of how hormonal shifts drive biological aging, and how to track whether your HRT protocol is actually working, read our definitive guide: Menopause, HRT & Biological Age: The Definitive Guide to Tracking Hormonal Aging.

What does HRT actually do to biological age?

Hormone replacement therapy shifts the IgG glycome (the collection of complex sugars (glycans) attached to immune antibodies) toward a more youthful, anti-inflammatory profile. Estradiol is the primary activator of anti-inflammatory glycan production, which is why its decline during perimenopause triggers a measurable pro-inflammatory shift. In clinical practice, optimized HRT calibrated to restore hormonal balance has shown an average biological age improvement of 15 years as measured by GlycanAge, based on clinical observations from the GlycanAge partner network. The effect is not cosmetic or symptomatic. It reflects a genuine change in immune aging biology.

Why does menopause accelerate biological aging so dramatically?

Menopause represents a critical window for immune system aging: as estrogen declines, IgG glycosylation shifts toward a pro-inflammatory profile, accelerating biological aging. Women can experience an increase in GlycanAge of over a decade during the menopausal transition, driven by the loss of estrogen's protective role in maintaining anti-inflammatory glycan structures. This shift is driven by both estrogen deficiency and estrogen dominance, meaning hormonal balance matters as much as hormonal levels. GlycanAge data shows an acceleration of approximately 10 years on average as women transition into menopause. In women who go on to receive well-managed HRT, clinical data consistently shows meaningful biological age reductions, though the degree of reversal varies by individual, formulation, and timing of initiation.

"When estrogen levels are low or non-existent, we get a pro-inflammatory state. We have to think of menopause as a long-term hormone deficiency — for most women, it lasts around 30 years."

— Dr. Louise Newson, Menopause Specialist and GP, The Age of You podcast

Is there clinical trial evidence that estrogen directly causes this aging shift?

"When you block the hormones — whether estrogen or testosterone — IgG glycans change rapidly. People can age 10 to 20 years within a couple of months of stopping hormone production. When you restore the hormones, that doesn't happen."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

GlycanAge, in collaboration with researchers at the University of Colorado Anschutz Medical Campus, conducted a placebo-controlled, randomized trial in which suppression of gonadal hormones in healthy premenopausal women produced a marked increase in biological age. Estradiol add-back therapy effectively prevented this change, confirming that estrogen depletion, not aging itself, is the key driver of the inflammatory shift. In a separate placebo-controlled study, women with temporarily suppressed estrogen aged nine years within six months; women given estrogen back showed no aging effect and remained at their healthy baseline. This is among the most direct evidence available that estrogen functions as a longevity therapeutic, not merely a symptom-management tool.

Is estrogen a longevity drug, or is that an overstatement?

The case for estrogen as a longevity therapeutic is supported by increasingly direct mortality data. A 2024 UK Biobank analysis by Morin et al. examined 406 commonly prescribed medications across a cohort of over 500,000 individuals and found that 14 were associated with reduced all-cause mortality. Estrogen-based therapies, including Estraderm, Vagifem, Estradiol, and Estriol, produced the strongest effects among all 406 drugs evaluated, with hazard ratios between 0.67 and 0.75, representing a 25–33% reduction in mortality risk. The evidence now supports framing HRT not as symptom relief but as preventive medicine for immune aging.

Does HRT work the same way for everyone, or does the response vary?

The biological age benefit of HRT varies by formulation, dosage, timing, and individual response, and must be interpreted in clinical context. Preliminary longitudinal data from approximately 40 women receiving HRT show consistent reductions in biological age and pro-inflammatory glycans over time, though two women in the cohort moved in the opposite direction, underscoring that personalization matters. In one clinical case, a 55-year-old woman switching from oral estrogen-progesterone therapy to bioidentical estradiol cream saw a reduction of 10 biological years over 12 months. In another, a 56-year-old HRT-naïve woman initiated transdermal estradiol, testosterone, DHEA, and progesterone; her GlycanAge reduced by 8 years within three months and by 11 years after one year. These cases illustrate why GlycanAge is used as an objective guide for dosing, monitoring response, and adjusting therapy over time alongside symptom improvement.

"With optimized hormone replacement, I've seen patients drop 20–25 years off their GlycanAge. This isn't just about relieving menopausal symptoms — it's about showing measurable improvements in biological age and inflammation. For the first time, we can prove the systemic benefits of HRT with objective data, and that changes the conversation from short-term relief to long-term health and longevity."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical

Does testosterone replacement also lower biological age in men?

The biological age benefit of testosterone in men depends on its conversion to estrogen. In a placebo-controlled study, testosterone produced a positive effect on glycan-measured biological age only when it was allowed to convert to estradiol; blocking that conversion with an aromatase inhibitor produced a pro-inflammatory effect. This means the beneficial effect of healthy testosterone levels in men operates largely through estrogen, a finding that is also visible in clinical practice, where estrogen levels are a stronger predictor of glycan profile than testosterone levels alone. One clinical case of a 73-year-old man on long-term testosterone who had been given an aromatase inhibitor demonstrated the negative inflammatory consequence of blocking this conversion.

How do I use GlycanAge to monitor whether my HRT is actually working?

GlycanAge is used clinically as an objective baseline before initiating HRT and as a monitoring tool to track whether therapy is shifting the glycan profile in the right direction. The HRT prescribing algorithm developed for clinical use, credited to Dr. Simisola Oke, uses GlycanAge results to determine whether HRT is required, guide formulation choice based on clinical presentation, and set a retest cadence of six months for those not yet on therapy. Glycan changes that indicate a positive response include increased galactosylation (reflected in the Glycan Youth index) and increased sialylation (reflected in the Glycan Shield index). Because GlycanAge measures active, current inflammation rather than a historical snapshot, a meaningful change in result reflects a real biological shift, not measurement noise.

Is HRT safe, and how should I think about the Women's Health Initiative findings?

The Women's Health Initiative study published in 2002 caused a precipitous drop in HRT prescriptions worldwide, but its findings have since been substantially reinterpreted. The study was widely regarded as flawed in both design and interpretation; reanalysis has shown that the timing of HRT initiation relative to menopause is a critical variable that the original study failed to account for. Critically, the formulation used in the WHI (oral conjugated equine estrogens combined with synthetic progestins) is fundamentally different from the bioidentical, transdermal 17β-estradiol now standard in clinical practice. Transdermal estradiol carries no excess clot or stroke risk, bypasses first-pass liver metabolism, and is now widely recognized as safe when properly titrated and managed. Contraindications exist, including hormone-sensitive cancers, and HRT is not appropriate for every woman, which is precisely why objective biological monitoring matters.

If you are perimenopausal or menopausal and want to measure whether your HRT is working at a biological level, not just symptom level, a GlycanAge test gives you and your clinician an objective, inflammation-based baseline before you start and a measurable signal of response over time. Order your at-home test kit and book your 1:1 result interpretation call to see exactly where your immune age stands today.

Order Your GlycanAge Test Kit

External sources

• https://pubmed.ncbi.nlm.nih.gov/39364726/ — Morin J, Rolland Y, Bischoff-Ferrari HA, Ocampo A, Perez K. Association between prescription drugs and all-cause mortality risk in the UK population. Aging Cell. 2024 Dec;23(12):e14334.

• https://pubmed.ncbi.nlm.nih.gov/33049709/ — Jurić J, Kohrt WM, Kifer D, Gavin KM, Pezer M, et al. Effects of estradiol on biological age measured using the glycan age index. Aging (Albany NY). 2020 Oct 13;12(19):19756–19778.

• https://pubmed.ncbi.nlm.nih.gov/28239652/ — Ercan A, Kohrt WM, Cui J, Deane KD, Pezer M, et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight. 2017 Feb 23;2(4):e89703.

• https://www.nhlbi.nih.gov/science/womens-health-initiative-whi — Women's Health Initiative — National Heart, Lung, and Blood Institute.